| Literature DB >> 3761313 |
M G Bock, R M DiPardo, K E Rittle, B E Evans, R M Freidinger, D F Veber, R S Chang, T B Chen, M E Keegan, V J Lotti.
Abstract
Seventeen analogues of the selective, competitive cholecystokinin (CCK) antagonist asperlicin 1 were prepared. These compounds were tested as inhibitors of the binding of [125I]CCK to rat pancreas and guinea pig brain receptors. Compounds 4, 7, and 8 were more potent than asperlicin on the pancreatic CCK receptor. One analogue, 17, displayed potency equivalent to asperlicin on the pancreas CCK receptor and showed a marked improvement in aqueous solubility, thereby facilitating the use of this class of CCK antagonists in physiological and pharmacological studies.Entities:
Mesh:
Substances:
Year: 1986 PMID: 3761313 DOI: 10.1021/jm00160a024
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446